SCY-770 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

5,352 results for “SCY-770”

Trials

View all 3945 →

Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

24 participants · First posted Feb 2, 2010

Study of VX-770 on Desipramine

24 participants · First posted Jun 30, 2010

Approved For Marketing

VX-770 Expanded Access Program

First posted Jun 27, 2011

Drugs

View all 1095 →

DG-770

Investigational

SCY-635

C₆₆H₁₂₀N₁₂O₁₃S

SCY-575

Organizations

View all 35 →

OpSens, Inc.

Canada

Vakzine Projekt Management GmbH

Germany

Shilpa Medicare Ltd.

India

News

View all 277 →

SCYNEXIS Wins BARDA Contract Worth Up to $214M for Second-Generation Antifungal SCY-247

SCYNEXIS Receives FDA Fast Track and QIDP Designations for SCY-247 Antifungal Therapy

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247 for Invasive Fungal Infections

Page 1 of 536